Abstract
IntroductIon
The most common presentation of thyroid cancer is a newly discovered thyroid nodule or increase in size of a preexisting nodule; however, the vast majority of patients (95%) presenting in this manner have benign disease (1) . The long-term outcome of patients treated effectively for differentiated thyroid carcinoma (DTC) is usually favorable. The overall 10-year survival rate for middle-aged adults with DTC is 80 -90%. However, 5 -20% of patients develop local or regional recurrences and 10 -15% distant metastases. Nine per cent of patients with a diagnosis of thyroid cancer die of their disease (1) . British Thyroid Association Guidelines for the management of thyroid cancer (third edition) was published recently (July 2014) (1) . It must be added that European Consensus for the management of patients with DTC was published in 2006 (2) and the second edition of British Thyroid Association guidelines for the management of thyroid cancer was published one year after (2007) . All patients with thyroid cancer should be seen within a multidisciplinary team (MDT) framework. Different aspects of this topic (thyroid carcinoma) have been published in our country (3) (4) (5) (6) 
Thy3a (Atypical features) -Repeat FNAC Thy3f (Follicular neoplasm) -Diagnostic hemithyroidectomy Thy4 (Suspicious of malignancy) -Diagnostic hemithyroidectomy Thy5 (Malignancy) -Total / near total thyroidectomy *-in case of Thy2 associated with U3-U4, FNAC should be repeated patients with thyroid cancer should perform a minimum of 20 thyroidectomies per year. In patients with thyroid cancer assessment of extra-thyroidal extension and lymph nodes disease in the central and lateral neck compartments should be undertaken preoperatively. A combination of ultrasound (US) and computer tomography (CT)/MRI imaging is advised depending upon local expertise (1). Parathyroid glands should whenever possible be identified and preserved. If their vascular supply is compromised, the gland/s should be excised and re-implanted into muscle (1) . For patients with Thy3f or Thy4 FNAC, a diagnostic hemithyroidectomy is recommended. Total thyroidectomy is recommended for patients with tumors greater than 4 cm in diameter or tumors of any size in association with any of the following characteristics: multifocal disease, bilateral disease, extra-thyroidal spread (pT3 and pT4a), familial disease and those with clinically or radiologically involved nodes and/or distant metastases. Prophylactic central neck dissection is not recommended for patients without clinical or radiological evidence of lymph node involvement, who have all of the following characteristics: classical type papillary thyroid carcinoma (PTC), <45 years, unifocal tumour, < 4cm, no extra-thyroidal extension on US (1). Male gender has previously been considered as an additional risk factor for disease-specific survival, but two recent studies have failed to confirm that it is an independent risk factor for survival (7, 8) .
Post constitute approximately 30% of all DTC and are largely responsible for the rise in incidence of thyroid cancer seen in many countries over the past decade (1). Their management is one of the most controversial areas in thyroid cancer occupying a large proportion of MDT discussion time. Papillary microcarcinomas are often an incidental finding and distant metastases are documented in 0 -3% of cases at diagnosis. Reported local recurrence rates are in 3.8 -20%. Mortality is very rare; a meta-analysis which included 9379 patients identified 32 deaths (0.34%). Total thyroidectomy is recommended in patients with multifocal microPTC involving both lobes or for patients with microPTC and familial non-medullary thyroid cancer. Thyroid lobectomy is recommended for patients with unifocal microPTC (1) .
Radioiodine remnant ablation and radioiodine therapy in DTC.
Following a total or near total thyroidectomy, some radioiodine uptake is usually demonstrable in the thyroid bed. Radioiodine remnant ablation (RRA) is required for destruction of this residual thyroid tissue. Some disadvantages of RRA are the following: need to avoid pregnancy (6 months) or fathering a child (4 months), hospital stay in isolation, need to maintain a safe distance from others for a short period after treatment. For the purpose of RRA, patients can be classified into 3 categories: definite indications, uncertain indications and no indications for RRA. Patients in the "definite indications" category (tumor > 4 cm or any tumor size with gross extrathyroidal extension (pT4) or distant metastases present) should be advised to receive RRA. Patients in the "no indications" category (tumor < 1 cm unifocal or multifocal, classical PTC or follicular minimally invasive without angioinvasion and no invasion of thyroid capsule) should be advised against receiving RRA (1). The patient should be seen by an appropriate member of MDT, preferably in a multidisciplinary clinic, for assessment and discussion about the indication for RRA or radioiodine therapy. RRA and radioiodine treatment must be administered by centers suitably equipped and certified for the purpose. Informed consent should be obtained from the patient before treatment. Pregnancy must be excluded before RRA or radioiodine therapy is U1 -U5 scoring /grading system and Thy1 -Thy5 cytology classification (FNAC results) were not present in the European Consensus Dynamic risk stratification was not present in the European Consensus Two recent studies (8, 9) failed to confirm that mail gender is an independent risk factor for survival Solitary or limited bone metastases unresponsive to radioiodine should be considered for further treatment with one or more of the following modalities: EBRT, surgical resection, embolisation, thermal ablation, cement injection administered. Breastfeeding must be discontinued at least 8 weeks before RRA or radioiodine therapy and should not be resumed. Patients should be advised to adopt a low iodine diet for 2 weeks prior to RRA or radioiodine treatment. A minimum interval of 8 weeks is recommended between contrast enhanced radiological investigations and radioiodine administration. A stimulated Tg and neck US should be performed in preference to a diagnostic radioiodine whole body scan (WBS) between 9 and 12 months from radioiodine ablation. Patients treated with total thyroidectomy and RRA should undergo Dynamic Risk stratification, which facilitates followup. Clinical trials of Tyrosine Kinase Inhibitors in progressive, radioiodine refractory thyroid cancer are under way and may become available in the near future. Lifetime incidence of leukaemia and second cancers is low, affecting around 0.5% of patients.
Thyroid cancer in childhood. DTC is rare in children and children at particular risk are those previously exposed to radiotherapy to the head or neck. Thyroid nodules are more likely to be malignant in children than in adults. PTC in children aged 15 years or less is more aggressive than in adults, with a high prevalence of gross lymph node metastases at presentation ( 9) . However, disease specific mortality even in young patients with lung metastases is very low. Follicular thyroid carcinoma in children and adolescents up to 20 years of age is very rare. It must be added that MDT must include a pediatric endocrinologist. As the risks of complications from thyroidectomy are higher in children, it is recommended to be treated by a surgeon from MDT ( 9) . In patients with PTC, a total thyroidectomy and central compartment lymph node dissection are recommended in order to reduce the risk of local recurrences. Radioiodine remnant ablation (RRA) is recommended for all children particularly those aged under 10 years, but the decision about RRA should be individually determined. Follow-up with serial serum thyroglobulin (Tg) measurements should be lifelong.
Recurrent/persistent differentiated thyroid cancer (DTC). Supraphysiological doses of levothyroxine are used to reduce the risk of thyroid cancer recurrence. Adverse effects from longterm TSH suppression include increased risk of atrial fibrillation, cardiovascular disease and death as well as osteoporosis. In patients with an incomplete response to therapy for thyroid carcinoma, the serum TSH should be suppressed below 0.1 mU/l indefinitely, in the absence of specific contraindications. In patients with an excellent response to treatment, the serum TSH should be maintained in the low-normal range between 0.3 -2 mU/l. Suppressive levothyroxine therapy is best supervised by a member of the MDT, preferably by an endocrinologist. Thyroglobulin (Tg) is secreted by both normal and cancerous thyroid cells. Since Tg release is TSHdependent, serum TSH concentration should be determined concurrently to aid interpretation. A serum Tg rising with time while on suppressive thyroxine therapy is highly suggestive of tumor recurrence or progression. De novo appearance or a rising trend in TgAb
